Trials / Active Not Recruiting
Active Not RecruitingNCT04106219
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 71 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 2 Years – 21 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3295668 Erbumine | Administered orally. |
| DRUG | Topotecan | Administered IV. |
| DRUG | Cyclophosphamide | Administered IV. |
Timeline
- Start date
- 2020-06-11
- Primary completion
- 2022-04-13
- Completion
- 2026-08-01
- First posted
- 2019-09-26
- Last updated
- 2025-07-23
Locations
17 sites across 9 countries: United States, Australia, Belgium, France, Germany, Italy, Japan, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04106219. Inclusion in this directory is not an endorsement.